890012-50-7

Basic information

• Product Name: 3-(4-CHLOROPHENYL)-1H-PYRAZOLE-5-CARBOHYDRAZIDE
• Synonyms: TIMTEC-BB SBB009290;3-(4-CHLOROPHENYL)-1H-PYRAZOLE-5-CARBOHYDRAZIDE;AKOS BBS-00004531;AKOS B009114;5-(4-CHLORO-PHENYL)-2 H-PYRAZOLE-3-CARBOXYLIC ACID HYDRAZIDE;ART-CHEM-BB B009114
• CAS NO: 890012-50-7
• Molecular Formula: C₁₀H₉ClN₄O
• Molecular Weight: 236.66
• Mol File: 890012-50-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-CHLOROPHENYL)-1H-PYRAZOLE-5-CARBOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-CHLOROPHENYL)-1H-PYRAZOLE-5-CARBOHYDRAZIDE(890012-50-7)
• EPA Substance Registry System: 3-(4-CHLOROPHENYL)-1H-PYRAZOLE-5-CARBOHYDRAZIDE(890012-50-7)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 890012-50-7(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Upstream product

• 938182-43-5 5-(4-chloro-phenyl)-2H-pyrazole-3-carboxylic acid ethyl ester 
• 5814-38-0 ethyl 4-chlorobenzoylpyruvate 
• 99-91-2 para-chloroacetophenone 

Downstream Products

• 1393587-96-6 (+/-)-3-(4-chlorophenyl)-N-(2-(2-nitrophenyl)-4-oxothiazolidin-3-yl)-1H-pyrazole-5-carboxamide 
• 1393587-97-7 (+/-)-3-(4-chlorophenyl)-N-(2-(3-nitrophenyl)-4-oxothiazolidin-3-yl)-1H-pyrazole-5-carboxamide 
• 1393587-98-8 (+/-)-3-(4-chlorophenyl)-N-(2-(2-chlorophenyl)-4-oxothiazolidin-3-yl)-1H-pyrazole-5-carboxamide 
• 1393587-99-9 (+/-)-3-(4-chlorophenyl)-N-(2-(4-chlorophenyl)-4-oxothiazolidin-3-yl)-1H-pyrazole-5-carboxamide 
• 1284275-59-7 (E)-N'-(4-chlorobenzylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 
• 1393587-74-0 (E)-N'-(2-chlorobenzylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 
• 1285537-05-4 (E)-N'-(3-nitrobenzylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 
• 1393587-66-0 (E)-N'-benzylidene-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 
• 1393587-71-7 (E)-N'-(4-hydroxybenzylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 
• 1284268-03-6 (E)-N'-(4-methoxybenzylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 
• 1393587-70-6 (E)-N'-(2-hydroxybenzylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 
• 1393587-69-3 (E)-N'-(4-hydroxy-3-methoxybenzylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 
• 1393587-68-2 (E)-N'-(3,4-dimethoxybenzylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 
• 1393587-72-8 (E)-N'-(2-nitrobenzylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide 

Relevant articles and documents

Pyrazole-oxadiazole conjugates: Synthesis, antiproliferative activity and inhibition of tubulin polymerization

A number of pyrazole-oxadiazole conjugates were synthesized and evaluated for their ability to function as antiproliferative agents on various human cancer cell lines. These conjugates are comprised of pyrazole and oxadiazole scaffolds closely attached to each other without any spacer as two structural classes. The Type I class has a trimethoxy substituent and the type II class has a 3,4-(methylenedioxy) substituent on their A rings. Among these conjugates, 11a, 11d and 11f manifest potent cytotoxicity with IC50values ranging from 1.5 μM to 11.2 μM and inhibit tubulin polymerization with IC50values of 1.3 μM, 3.9 μM and 2.4 μM respectively. The cell cycle assay showed that treatment with these conjugates results in accumulation of cells in the G2/M phase and disrupts the microtubule network. Elucidation of zebrafish embryos revealed that the conjugates cause developmental defects. Molecular docking simulations determined the binding modes of these potent conjugates at the colchicine site of tubulin.

Synthesis, Structure-Activity Relationship, and Pharmacophore Modeling Studies of Pyrazole-3-Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors

Type 2 diabetes mellitus (T2DM) is a metabolic disease and a major challenge to healthcare systems around the world. Dipeptidyl peptidase IV (DPP-4), a serine protease, has been rapidly emerging as an effective therapeutic target for the treatment for T2DM. In this study, a series of novel DPP-4 inhibitors, featuring the pyrazole-3-carbohydrazone scaffold, have been discovered using an integrated approach of structure-based virtual screening, chemical synthesis, and bioassay. Virtual screening of SPECS Database, followed by enzymatic activity assay, resulted in five micromolar or low-to-mid-micromolar inhibitory level compounds (1-5) with different scaffold. Compound 1 was selected for the further structure modifications in considering inhibitory activity, structural variability, and synthetic accessibility. Seventeen new compounds were synthesized and tested with biological assays. Nine compounds (6e, 6g, 6k-l, and 7a-e) were found to show inhibitory effects against DPP-4. Molecular docking models give rational explanation about structure-activity relationships. Based on eight DPP-4 inhibitors (1-5, 6e, 6k, and 7d), the best pharmacophore model hypo1 was obtained, consisting of one hydrogen bond donor (HBD), one hydrogen bond acceptor (HBA), and two hydrophobic (HY) features. Both docking models and pharmacophore mapping results are in agreement with pharmacological results. The present studies give some guiding information for further structural optimization and are helpful for future DPP-4 inhibitors design.

Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives

As a part of our research to develop novel antitubercular and antimicrobial agents, a series of 3-(4-chlorophenyl)-4-substituted pyrazoles have been synthesised. These compounds were tested for antitubercular activity in vitro against Mycobacterium tuberc

Synthesis, X-ray crystal structure and optical properties of novel 5-(3-aryl-1H-pyrazol-5-yl)-2-(6-methoxy-3-methylbenzofuran-2-yl)-1,3, 4-oxadiazole

A series of novel 5-(3-aryl-1H-pyrazol-5-yl)-2-(6-methoxy-3- methylbenzofuran-2-yl)-1,3,4-oxadiazole derivatives has been synthesized from 6-methoxy-3-methylbenzofuran-2-carboxylic acid and ethyl 3-aryl-1H-pyrazole-5- carboxylate. The structures of compou